AstraZeneca discontinued the eVOLVE-Lung02 trial on August 18, 2026.
1 report, 1 independent
Updated Aug 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AstraZeneca discontinued the eVOLVE-Lung02 trial on August 18, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- AstraZeneca's drug was tested in collaboration with Pfizer's drug.
- Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.
- Joint drug trial success boosts Amgen stock.
- Amgen and AstraZeneca co-developed the severe asthma drug TEZSPIRE, prompting an analyst to raise the price target.